{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T16:34:23Z","timestamp":1792946063594,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jacadv.2026.103306","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:08:50Z","timestamp":1791202130000},"page":"103306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Comparative Efficacy of Treatments for Resistant or Uncontrolled Hypertension"],"prefix":"10.1016","volume":"5","author":[{"given":"Angelo","family":"Laino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Pio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-2836","authenticated-orcid":false,"given":"Raffaele","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5394-0192","authenticated-orcid":false,"given":"Anna","family":"Franzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-7127","authenticated-orcid":false,"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.103306_bib1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103306_bib2","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.116.303641","article-title":"Randomized controlled trials of blood pressure lowering in hypertension","volume":"116","author":"Zanchetti","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jacadv.2026.103306_bib3","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.jacadv.2026.103306_bib4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103306_bib5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jclinepi.2005.03.004","article-title":"Searching one or two databases was insufficient for meta-analysis of observational studies","volume":"58","author":"Lemeshow","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jacadv.2026.103306_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101686","article-title":"New dual endothelin receptor antagonist aprocitentan in hypertension: a systematic review and meta-analysis","volume":"48","author":"Mahfooz","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacadv.2026.103306_bib8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.124.069709","article-title":"Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis","volume":"150","author":"Vukadinovi\u0107","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103306_bib9","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2026.103306_bib10","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103306_bib11","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 11: Undertaking network meta-analyses [last updated October 2019]","author":"Chaimani","year":"2024"},{"key":"10.1016\/j.jacadv.2026.103306_bib12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jacadv.2026.103306_bib14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jacadv.2026.103306_bib15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2026.103306_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s11606-017-4000-7","article-title":"A network meta-analysis of clinical management strategies for treatment-resistant hypertension: making optimal use of the evidence","volume":"32","author":"Makai","year":"2017","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejim.2023.04.021","article-title":"A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension","volume":"113","author":"Ahmed","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/cvr\/cvad165","article-title":"Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis","volume":"120","author":"Tian","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2026.103306_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2026.103306_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacadv.2026.103306_bib23","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103306_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","article-title":"A meta-analysis of add-on use of spironolactone in patients with resistant hypertension","volume":"233","author":"Zhao","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacadv.2026.103306_bib25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/HJH.0000000000001671","article-title":"Effect of mineralocorticoid antagonists on blood pressure lowering","volume":"36","author":"Bazoukis","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacadv.2026.103306_bib26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103306_bib27","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(23)00733-X","article-title":"Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients","volume":"401","author":"Staplin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103306_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"Comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacadv.2026.103306_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103306_bib30","doi-asserted-by":"crossref","first-page":"R633","DOI":"10.1152\/ajpregu.00258.2005","article-title":"Physiology in perspective: the Wisdom of the body. Neural control of the kidney","volume":"289","author":"DiBona","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jacadv.2026.103306_bib31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1161\/CIRCULATIONAHA.123.066941","article-title":"Patient-level pooled analysis of endovascular ultrasound renal denervation or a sham procedure 6 months after medication escalation: the RADIANCE clinical trial program","volume":"149","author":"Azizi","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103306_bib32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4244\/EIJ-D-23-00088","article-title":"Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications","volume":"19","author":"Pathak","year":"2023","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacadv.2026.103306_bib33","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103306_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jama.2023.0713","article-title":"Endovascular ultrasound renal denervation to treat hypertension","volume":"329","author":"Azizi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.103306_bib35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","article-title":"Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC council on hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"44","author":"Barbato","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103306_bib36","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMe2511533","article-title":"Aldosterone synthase inhibition for hypertension","volume":"393","author":"Guzik","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib37","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103306_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJMe2216143","article-title":"Decreasing the effects of aldosterone. in resistant hypertension \u2014 a success story","volume":"388","author":"Azizi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib39","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(25)01153-5","article-title":"Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"406","author":"Pyne","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103306_bib40","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.103306_bib41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2215-0366(24)00136-6","article-title":"Psychological and psychosocial interventions for treatment-resistant schizophrenia: a systematic review and network meta-analysis","volume":"11","author":"Salahuddin","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jacadv.2026.103306_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/tbm\/ibz133","article-title":"Measuring the multiple domains of medication nonadherence: findings from a Delphi survey of adherence experts","volume":"11","author":"Kronish","year":"2021","journal-title":"Transl Behav Med"},{"key":"10.1016\/j.jacadv.2026.103306_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/08037051.2025.2513434","article-title":"Patient perceptions, motivations and barriers to treatment adherence in hypertension: results of a questionnaire-based survey in five European countries","volume":"34","author":"Burnier","year":"2025","journal-title":"Blood Press"},{"key":"10.1016\/j.jacadv.2026.103306_bib44","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/HYPERTENSIONAHA.124.22072","article-title":"Genetic and epigenetic mechanisms regulating blood pressure and kidney dysfunction","volume":"81","author":"Pandey","year":"2024","journal-title":"Hypertension"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T15:51:11Z","timestamp":1792943471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26007283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2772963X26007283"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103306","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of Treatments for Resistant or Uncontrolled Hypertension","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103306"}}